Biology and Regenerative Medicine and HHMI, has pioneered the use of
synthetic small molecules and natural products to manipulate activities
of developmental and stem cell signaling pathways in vitro and in vivo.
* Sheng Ding, Ph.D., Scripps Research Institute, has worked on the
identification of small molecules and genes that control cell fate,
including cell reprogramming and differentiation. Dr. Ding's work has
important implications for the development of small molecule drugs that
can potentiate adult stem cells in vivo, and reprogram differentiated
cells to new functions.
* Randall Moon, Ph.D., University of Washington; Director, Institute for
Stem Cell and Regenerative Medicine; HHMI; and UW Department of
Pharmacology, has focused on illuminating the biological pathways that
control adult stem cells during the process of regeneration to develop
new therapeutic methods to activate regeneration.
* David Scadden, M.D., Professor, Harvard University; Co-Director and
Co-Founder, Harvard Stem Cell Institute; Director, Massachusetts
General Hospital Center for Regenerative Medicine, has broken new
ground in understanding how blood forming stem cells and other adult
stem cells are maintained in the adult body in specialized niches, and
in developing therapies that exploit this biology to modulate adult
stem cells in vivo.
* Leonard Zon, M.D., Harvard University; Director of the Stem Cell
Program, Children's Hospital of Boston; and HHMI, is a world expert on
the biology of adult blood forming stem cells and methods of enhancing
their function for cancer and regenerative medicine applications.
Formed in early 2007, Fate Therapeutics raised $15 million in its
Series A fin
|SOURCE Fate Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved